Search
for

    Sort by

    Community Join

    180-210 / 1000+ results

      community Pyrilutamide Phase 3 on its way

      in Treatment  128 upvotes 4 years ago
      Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

      community About GT20029's Efficacy and Strength

      in Chat  7 upvotes 3 years ago
      The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

      community Has anyone hear of the drug called Xeljanz?

      in Question  3 upvotes 9 years ago
      The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and Xeljanz. The user inquires about Xeljanz and shares a link suggesting it may help with hair loss.

      community CB-03-01 users come forward!

       13 upvotes 6 years ago
      The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

      community How would you react if PP405 isn't successful in phase 3 trials?

      in Chat  23 upvotes 6 months ago
      People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

      community Pelage are going to do two phase 3 trials for PP405. How long will it take to complete two phase 3 trials?

      in Chat  45 upvotes 5 months ago
      Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

      community Hives/Rash from Kx 826 Pyrilutamide???

      in Chat  1 upvotes 1 year ago
      OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

      community Any chemists want to manufacture PP405 / JXL069? (Steps inside)

      in Research/Science  89 upvotes 7 months ago
      The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

      community Has anyone tried KeraXL before?

      in Treatment  1 upvotes 3 years ago
      A user discussed using KeraXL serum for hair loss, which contains Biochanin-A from Red clover extract and Acetyl Tetrapeptide-3. They sought feedback on its safety and effectiveness.

      community Any good place to buy KX-826, AHK‑Cu and PTD-DBM?

      in Product  1 upvotes 2 months ago
      The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

      community Does anyone have experience with KY19382?

      in Research/Science  3 upvotes 5 months ago
      KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

      community Update and new paper from Dr tsuji

      in Update  25 upvotes 7 years ago
      Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

      community Has anyone used Magnesium L-Threonate ?

       70 upvotes 7 years ago
      Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.

      community Ru-58841 or KX-826 (Pyrilutamide)?

      in Treatment  11 upvotes 3 years ago
      Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.

      community CB-03-01: I need help

      in Treatment  7 upvotes 5 years ago
      The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

      community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES

      in Treatment  18 upvotes 5 years ago
      The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.